Real-World Analysis of Gastric and Gastroesophageal Junction Cancer in Mexico: Demographic and Clinical Characteristics
Author(s)
Monica Isabel Meneses, MD1, Consuelo Diaz Romero, MD2, Ricardo Flores Lopez, MD3, Victoria Castillo, MD4, Maria Alejandra Betancur, MD5, Sebastian Medina, MD5, Gaby Lugo6, Georgina del Carmen Filio Rodriguez, phD7.
1Instituto Nacional de Nutrición Y ciencias Médicas Salvador Zubirán, CDMX, Mexico, 2INCAN, MEXICO, Mexico, 3Instituto National de Cancerologia, Mexico City, Mexico, 4TIS, CDMX, Mexico, 5MSD, Colombia, Colombia, 6MD, MSD, Cdmx, Mexico, 7MSD, MEXICO, Mexico.
1Instituto Nacional de Nutrición Y ciencias Médicas Salvador Zubirán, CDMX, Mexico, 2INCAN, MEXICO, Mexico, 3Instituto National de Cancerologia, Mexico City, Mexico, 4TIS, CDMX, Mexico, 5MSD, Colombia, Colombia, 6MD, MSD, Cdmx, Mexico, 7MSD, MEXICO, Mexico.
Presentation Documents
OBJECTIVES: Gastroesophageal junction (GEJ) and gastric cancer are the sixth leading cause of cancer death in Mexican adults over 20, with outcomes impacted by delayed oncological care and the lack of a national treatment consensus. This study aims to deepen the understanding of the demographic and clinical characteristics of gastric and GEJ cancer patients in real-world settings in Mexico
METHODS: This retrospective study analyzed structured secondary data from two major Mexican hospitals: INCMNSZ and INCan. Patients newly diagnosed with gastric or GEJ adenocarcinoma between 2005 and 2019 were included. Patients aged 18 or older with histologically verified diagnoses and no prior therapy were eligible. Exclusion criteria included follow-up <3 years (except for those patients who die within 3 years). This phase of the study presents only demographic and disease staging data
RESULTS: A total of 653 patients were analyzed, with a mean age of 54 years (range: 20-94). The cohort consisted of 55% females and 45% males, resulting in a female-to-male ratio of 1.2:1. Patients had a mean weight of 58.8 kg (range: 24-107.6), mean height of 1.59 m (range: 1.34-1.90), and an average body mass index (BMI) of 23.3 kg/m² (range: 11.57-42.03). Alcohol use was reported by 24% of patients, while 70% of patients reported using tobacco. HER2 expression was assessed in 27.5% of cases, with 10.05% testing positive. 80.8% of patients were diagnosed at an advanced stage (EC 4). Stages 3C (3.68%) and 3A (3.83%) followed in frequency, while early stages such as 1A (1.68%) and 1B (1.23%) were the least common.
CONCLUSIONS: The notable delays in the early detection of gastric and GEJ cancer highlight the urgent need for strategies aimed at improving early detection, managing risk factors, and establishing standardized treatment protocols to improve clinical outcomes for this population.
METHODS: This retrospective study analyzed structured secondary data from two major Mexican hospitals: INCMNSZ and INCan. Patients newly diagnosed with gastric or GEJ adenocarcinoma between 2005 and 2019 were included. Patients aged 18 or older with histologically verified diagnoses and no prior therapy were eligible. Exclusion criteria included follow-up <3 years (except for those patients who die within 3 years). This phase of the study presents only demographic and disease staging data
RESULTS: A total of 653 patients were analyzed, with a mean age of 54 years (range: 20-94). The cohort consisted of 55% females and 45% males, resulting in a female-to-male ratio of 1.2:1. Patients had a mean weight of 58.8 kg (range: 24-107.6), mean height of 1.59 m (range: 1.34-1.90), and an average body mass index (BMI) of 23.3 kg/m² (range: 11.57-42.03). Alcohol use was reported by 24% of patients, while 70% of patients reported using tobacco. HER2 expression was assessed in 27.5% of cases, with 10.05% testing positive. 80.8% of patients were diagnosed at an advanced stage (EC 4). Stages 3C (3.68%) and 3A (3.83%) followed in frequency, while early stages such as 1A (1.68%) and 1B (1.23%) were the least common.
CONCLUSIONS: The notable delays in the early detection of gastric and GEJ cancer highlight the urgent need for strategies aimed at improving early detection, managing risk factors, and establishing standardized treatment protocols to improve clinical outcomes for this population.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
CO100
Topic
Clinical Outcomes
Topic Subcategory
Clinician Reported Outcomes
Disease
SDC: Gastrointestinal Disorders, SDC: Oncology